User login
Key clinical point: Combination of bevacizumab with S-1 and irinotecan vs 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) as the first-line treatment for metastatic colorectal cancer (mCRC) showed comparable overall survival and noninferior progression-free survival (PFS).
Major finding: During a median follow-up of 48.7 months, median survival and PFS in patients assigned to bevacizumab+mFOLFOX6/CapeOX vs bevacizumab+S-1/irinotecan were 32.6 months vs 34.3 months (hazard ratio [HR], 0.89; P = .293) and 10.8 months vs 14.0 months (HR, 0.86; P less than .0001 for noninferiority), respectively. Safety results were as reported previously.
Study details: Findings are from phase 3 TRICOLORE trial including 487 patients with previously untreated mCRC who were randomly assigned to receive bevacizumab+mFOLFOX6/CapeOX or bevacizumab+S-1 and irinotecan.
Disclosures: This study was funded by Tokyo Cooperative Oncology Group with funding from Taiho Pharmaceutical Co. Ltd., Japan. Some of the authors including the lead author declared receiving honoraria, research funding, and/or consulting fees from various sources.
Source: Denda T et al. Eur J Cancer. 2021 Jul 22. doi: 10.1016/j.ejca.2021.06.013.
Key clinical point: Combination of bevacizumab with S-1 and irinotecan vs 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) as the first-line treatment for metastatic colorectal cancer (mCRC) showed comparable overall survival and noninferior progression-free survival (PFS).
Major finding: During a median follow-up of 48.7 months, median survival and PFS in patients assigned to bevacizumab+mFOLFOX6/CapeOX vs bevacizumab+S-1/irinotecan were 32.6 months vs 34.3 months (hazard ratio [HR], 0.89; P = .293) and 10.8 months vs 14.0 months (HR, 0.86; P less than .0001 for noninferiority), respectively. Safety results were as reported previously.
Study details: Findings are from phase 3 TRICOLORE trial including 487 patients with previously untreated mCRC who were randomly assigned to receive bevacizumab+mFOLFOX6/CapeOX or bevacizumab+S-1 and irinotecan.
Disclosures: This study was funded by Tokyo Cooperative Oncology Group with funding from Taiho Pharmaceutical Co. Ltd., Japan. Some of the authors including the lead author declared receiving honoraria, research funding, and/or consulting fees from various sources.
Source: Denda T et al. Eur J Cancer. 2021 Jul 22. doi: 10.1016/j.ejca.2021.06.013.
Key clinical point: Combination of bevacizumab with S-1 and irinotecan vs 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) as the first-line treatment for metastatic colorectal cancer (mCRC) showed comparable overall survival and noninferior progression-free survival (PFS).
Major finding: During a median follow-up of 48.7 months, median survival and PFS in patients assigned to bevacizumab+mFOLFOX6/CapeOX vs bevacizumab+S-1/irinotecan were 32.6 months vs 34.3 months (hazard ratio [HR], 0.89; P = .293) and 10.8 months vs 14.0 months (HR, 0.86; P less than .0001 for noninferiority), respectively. Safety results were as reported previously.
Study details: Findings are from phase 3 TRICOLORE trial including 487 patients with previously untreated mCRC who were randomly assigned to receive bevacizumab+mFOLFOX6/CapeOX or bevacizumab+S-1 and irinotecan.
Disclosures: This study was funded by Tokyo Cooperative Oncology Group with funding from Taiho Pharmaceutical Co. Ltd., Japan. Some of the authors including the lead author declared receiving honoraria, research funding, and/or consulting fees from various sources.
Source: Denda T et al. Eur J Cancer. 2021 Jul 22. doi: 10.1016/j.ejca.2021.06.013.